The results showed that the combination therapy of multiple drugs had significant therapeutic effect on chronic lymphocytic leukemia

Recently, a clinical trial (http:// showed that targeted therapy composed of three drugs (http:// has significant therapeutic effect on chronic lymphocytic leukemia (CLL), and can reduce the long-term negative effect caused by chemotherapy This clinical Ib / II trial was led by Dr Kerry Rogers and other researchers from the comprehensive cancer research center of Ohio State University They explored the therapeutic effect of two most effective drugs targeting CLL (ibrutinib, obinutuzumab) and a combination of monoclonal antibody (obinutuzumab) on CLL patients (relapse before and after treatment) The preliminary results showed that the combination therapy was safe and well tolerated for more than 96% of patients The combination therapy also has some complex effects, but it is similar to the single drug treatment and belongs to the controllable range In addition, patients will not have fatal side effects under the treatment of effective dose, and the killing effect of cancer cells is quite obvious The content of cancer cells can be detected in the blood (http:// This trial is the first to reveal the effect of three drugs combined with targeted therapy in CLL patients who have never been treated before.